2-isopropoxypyrazine | 65032-05-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-isopropoxypyrazine
• 英文别名: Isopropoxypyrazin；isopropoxy-pyrazine；2-[(Propan-2-yl)oxy]pyrazine；2-propan-2-yloxypyrazine
• CAS: 65032-05-5
• 化学式: C₇H₁₀N₂O
• 分子量: 138.169
• InChiKey: HXTSOMZAFUTVCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-isopropoxypyrazine 生成 羟基吡嗪
  参考文献：
  名称：

  吡嗪的研究。第8部分。2-烷氧基吡嗪的热解；取代基效应和立体特异性

  摘要：

  十二个2-烷氧基吡嗪（R = Pr i，Bu s，1,2-二甲基丙基，1,2,2-三甲基丙基，叔丁基，叔戊基，1,1,2-三甲基丙基，1,1,2,2 -四甲基丙基，辛基，新戊基，±-赤-和±-苏-2-（氘-1,2-二苯乙基）已被热解，以阐明取代基对反应速率和立体特异性的影响。确定了列出的前八种化合物的活化参数（log A和E a）。通过α取代促进了反应。这是极性和空间效应的结合。反应的立体特异性很高。

  DOI：

  10.1039/p29840000641
• 作为产物：
  描述：

  2-氯吡嗪 、 丙醇 在 sodium 作用下， 反应 2.0h， 以59%的产率得到2-isopropoxypyrazine
  参考文献：
  名称：

  Al-Awardi, Nouria; Taylor, Roger, Journal of the Chemical Society. Perkin transactions II, 1986, p. 1585 - 1588

  摘要：

  DOI：

文献信息

• BORON-CONTAINING SMALL MOLECULES
  申请人：Xia Yi

  公开号：US20100256092A1

  公开（公告）日：2010-10-07

  This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.

  这项发明涉及6-取代苯硼酯化合物等物品，以及它们用于治疗细菌感染的用途。
• NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY
  申请人：Iikura Hitoshi

  公开号：US20100004233A1

  公开（公告）日：2010-01-07

  The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y 1 and Y 2 are selected from —N═ etc., Y 3 and Y 4 are selected from —CH═ etc., A is selected from sulfamide etc., R 1 is selected from hydrogen etc., and R 2 is selected from C 1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

  本发明提供了一个由下式（1）所表示的化合物或其药学上可接受的盐： 其中，X选择自杂环芳基等，Y1和Y2选择自—N═等，Y3和Y4选择自—CH═等，A选择自磺酰胺等，R1选择自氢等，R2选择自C1-6烷基等。该化合物或盐具有足够高的抗肿瘤活性，并且在治疗细胞增殖性疾病，特别是癌症方面有用。本发明还提供了一种含有该化合物或盐作为活性成分的药物组合物。
• Novel Coumarin Derivative Having Antitumor Activity
  申请人：Iikura Hitoshi

  公开号：US20110092700A1

  公开（公告）日：2011-04-21

  The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y 1 and Y 2 are selected from —N═ etc., Y 3 and Y 4 are selected from —CH═ etc., A is selected from sulfamide etc., R 1 is selected from hydrogen etc., and R 2 is selected from C 1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

  本发明提供一种由下式（1）或其药学上可接受的盐所表示的化合物：其中，X选自杂环芳基等；Y1和Y2选自—N═等；Y3和Y4选自—CH═等；A选自磺酰胺等；R1选自氢等；R2选自C1-6烷基等。该化合物或盐具有足够高的抗肿瘤活性，并可用于治疗细胞增殖性疾病，特别是癌症。本发明还提供一种含有该化合物或盐作为活性成分的制药组合物。
• N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160272592A1

  公开（公告）日：2016-09-22

  Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  式I的化合物或其立体异构体、互变异构体、药学上可接受的盐、溶剂化合物或前药，其中环A、环C、X、Ra、Rb、Rc、Rd和n的定义如本文所述，是TrkA激酶的抑制剂，可用于治疗可通过TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、Sjogren综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或盆腔疼痛综合征。
• p27 Protein Inducer
  申请人：Sakai Toshiyuki

  公开号：US20110009398A1

  公开（公告）日：2011-01-13

  The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G 1 , G 2 , G 3 and G 8 are each independently selected from —N═ etc., Ring G 6 is selected from divalent aryl etc., A is selected from amino etc., G 4 is selected from oxygen etc., G 5 is selected from oxygen etc., G 7 is selected from —CH 2 — etc., and R 2 is selected from C 1-6 alkyl etc.

  本发明提供了一种p27蛋白诱导剂，其包含以下通式（11）所表示的化合物或其药学上可接受的盐作为活性成分：其中G1，G2，G3和G8各自独立地选择自—N═等，环G6选择自双价芳基等，A选择自氨基等，G4选择自氧等，G5选择自氧等，G7选择自—CH2—等，R2选择自C1-6烷基等。